<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01389700</url>
  </required_header>
  <id_info>
    <org_study_id>PKD11791</org_study_id>
    <secondary_id>U1111-1118-6717</secondary_id>
    <nct_id>NCT01389700</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of SAR279356 in Patients Hospitalized in Intensive Care Unit and on Mechanical Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      - To determine the pharmacokinetics (PK) of a single intravenous (IV) dose of SAR279356
      administered to intensive care unit (ICU) patients on mechanical ventilation

      Secondary Objectives:

        -  To determine the safety and tolerability of SAR279356

        -  To evaluate the pharmacodynamics (PD) and immunogenicity of SAR279356

        -  Exploratory efficacy of SAR279356 on prevention of bacterial infections
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total study duration (from screening to last follow-up visit) is 91 days break down as
      follows:

        -  Screening: 1 day prior to dosing;

        -  Treatment period: one IV injection on Day 1;

        -  Follow-up period: 90 days
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in patient recruitment in the participating sites
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of SAR279356 : Ceoi, AUClast and CL</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic assay (OPA)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic killing assay (OPK)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of human anti-human antibodies (HAHA)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of infections</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Infection Prophylaxis</condition>
  <arm_group>
    <arm_group_label>SAR279356 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR279356 dose 1, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR279356 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR279356 dose 2, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, single administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR279356</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous infusion</description>
    <arm_group_label>SAR279356 dose 1</arm_group_label>
    <arm_group_label>SAR279356 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  ICU patients on mechanical ventilation at the time of randomization

          -  Patients or legally authorized representative (LAR) giving written informed consent.

        Exclusion criteria:

          -  Patients &lt;18 years of age;

          -  Documented Pseudomonas infection or colonization in the last 30 days;

          -  Immunocompromised patients

          -  Hypersensitivity to the study drug and/or to prior therapy with monoclonal antibodies;

          -  Patient who has taken other investigational drugs or prohibited therapy for this study
             within 1 month or 5 half-lives, whichever is longer;

          -  Patient or LAR who withdraws consent during the screening (starting from signed
             informed consent form);

          -  Acute liver injury related criteria at the time of study entry:

          -  Pregnant or breast-feeding women

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840010</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840020</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Pikeville</city>
        <state>Kentucky</state>
        <zip>41501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>July 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2011</study_first_posted>
  <disposition_first_submitted>March 17, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 17, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 14, 2014</disposition_first_posted>
  <last_update_submitted>November 25, 2014</last_update_submitted>
  <last_update_submitted_qc>November 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

